Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,010 Shares of Stock

Key Points

• Multiple insiders sold shares on March 17, including Xiaolin Wang (2,010 shares at $99.48, ≈$200k) and Mark A. Goldsmith (12,871 shares, ≈$1.28M), each reducing their ownership by a few percentage points.
• RVMD shares trade around $99.29 with a market cap of $19.68B, yet the analyst consensus price target is $78.94 and the company recently missed quarterly EPS (‑$1.86 vs. ‑$1.56) with a fiscal‑year EPS forecast near ‑3.49.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Xiaolin Wang sold 2,010 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company's stock, valued at $11,545,947.24. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Revolution Medicines Stock Up 1.2%

Shares of NASDAQ RVMD traded up $1.18 during trading on Thursday, hitting $99.29. The stock had a trading volume of 1,485,201 shares, compared to its average volume of 2,335,170. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $124.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The company has a market capitalization of $19.68 billion, a PE ratio of -16.80 and a beta of 0.99. The firm has a fifty day moving average of $103.58 and a two-hundred day moving average of $76.24.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the firm posted ($1.12) EPS. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Neutral Sentiment: Jefferies Financial Group initiated coverage of Revolution Medicines, bringing fresh analyst attention that can boost visibility and trading interest but whose impact depends on the firm's published rating and price target (not specified in the entry). Jefferies Initiates Coverage
• Negative Sentiment: Insider sale — Xiaolin Wang sold 2,010 shares at an average $99.48 (≈$200k); holding fell ~1.70%, leaving ~116k shares. Multiple officer sales on the same day can be read negatively by the market. SEC Filing
• Negative Sentiment: Insider sale — CFO Jack Anders sold 2,753 shares at $99.48 (≈$274k); his stake declined ~2.15%, now ~125.5k shares. SEC Filing
• Negative Sentiment: Insider sale — COO Margaret A. Horn sold 4,583 shares at $99.48 (≈$456k); her ownership fell ~2.83%, leaving ~157.6k shares. SEC Filing
• Negative Sentiment: Insider sale — Mark A. Goldsmith sold 12,871 shares at $99.48 (≈$1.28M); his holding decreased ~4.44%, leaving ~276.7k shares. Larger absolute size may attract investor attention. SEC Filing
• Negative Sentiment: Insider sale — Stephen Michael Kelsey sold 4,302 shares at $99.48 (≈$428k); his stake fell ~1.44%, leaving ~295.4k shares. SEC Filing
• Negative Sentiment: Insider sale — Lin Wei sold 2,073 shares at $99.48 (≈$206k); her holding declined ~2.00%, leaving ~101.4k shares. SEC Filing

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors have recently bought and sold shares of the company. New York State Common Retirement Fund lifted its holdings in Revolution Medicines by 39.3% during the 3rd quarter. New York State Common Retirement Fund now owns 119,807 shares of the company's stock worth $5,595,000 after purchasing an additional 33,821 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in Revolution Medicines during the 3rd quarter valued at about $921,000. NEOS Investment Management LLC increased its position in shares of Revolution Medicines by 34.7% during the third quarter. NEOS Investment Management LLC now owns 126,921 shares of the company's stock valued at $5,927,000 after buying an additional 32,694 shares during the period. Tema Etfs LLC increased its position in shares of Revolution Medicines by 34.7% during the third quarter. Tema Etfs LLC now owns 126,921 shares of the company's stock valued at $5,927,000 after buying an additional 32,694 shares during the period. Finally, Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Revolution Medicines in the third quarter worth about $587,000. Hedge funds and other institutional investors own 94.34% of the company's stock.

Wall Street Analyst Weigh In

RVMD has been the topic of a number of research analyst reports. Evercore upgraded Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, February 25th. Jefferies Financial Group started coverage on Revolution Medicines in a report on Monday. They set a "buy" rating on the stock. Wedbush restated an "outperform" rating on shares of Revolution Medicines in a research note on Friday, January 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Finally, Benchmark reiterated an "overweight" rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines presently has an average rating of "Buy" and a consensus price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.